Contract Development and Manufacturing Organizations (CDMOs) Market By Services (Development Services (Process and Chemical Development, Analytical Development, Formulation Development, Others), Analytical Research Services, Clinical & Commercial Manufacturing, Project Management, Supply Chain Management & Logistics Services, Regulatory Services, Others); By Application (Drug Substance (Active Pharmaceutical Ingredients (API), Intermediates, Others), Drug Products (Oral Solids (Tablets, Capsules, Mini-tablets, Powder, Others), Semi-solid (Creams, Ointments, Gels, Others), Liquid, Inhalation, Sterile, Others), Cell & Gene Therapy, Others); By Organization Size (Small and Medium Enterprises, Large Enterprises); By End Users (Pharmaceutical Companies, Biotechnology Companies, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
A contract development and manufacturing organizations (CDMOs) provides pharmaceutical and biotechnology companies with drug development and manufacturing services. CDMOs and pharmaceutical corporations collaborate to outsource drug development and drug manufacturing services amongst other services. Full-service CDMOs possess the capabilities to manage all types of drug research and manufacture, and work with clients who want to outsource all or only certain aspects of their process. The activities of contract development and manufacturing organizations (CDMOs) refer to the production of goods by a factory under the label or brand of another company. Contract manufacturers provide these services to a wide array of end users based on their own or the designs, formulas, and specifications provided by the respective business entity. Increasing therapeutic complexity and a lack of in-house manufacturing capabilities in many small pharmaceutical businesses are expected to drive contract development and manufacturing organizations (CDMOs) market expansion over the projected period.
The expanding pharmaceutical sector and increasing need for one-stop-shop CDMOs are the two main reasons which are anticipated to drive the global contract development and manufacturing organizations (CDMOs) market growth over the forecast period. However, due to different production lines and the requirement to comply with regulations, CDMOs face standardization issues, which is likely to hamper market expansion over the projection period. Some of the major players are proactively contributing towards the growth of contract development and manufacturing organizations (CDMOs) and providing niche services to the pharmaceutical and biotechnology companies, which specifically caters to their requirement. For instance, In 2019, Lonza, a significant provider of small molecule drug substances and intermediates, and one of the global contract development and manufacturing firm, delivered manufacturing services for over 300 commercial molecules, supported the development of over 700 pre-clinical and clinical molecules in small and large molecules, and also aided in the launch of ground-breaking autologous cell treatments.
The Covid-19 pandemic impacted CDMOs worldwide. Demand for contract development and manufacturing organizations (CDMOs) is growing as COVID-19 vaccines and treatments are rolled out over the world. During the crisis, CDMOs had undertaken considerable initiatives to tackle the demands of their biopharmaceutical customers. Pharma businesses were faced with the issue of manufacturing millions of dosages that would be required in the event of a pandemic. CDMOs, on the other hand, were the most prominent source of increased capacity. Significant amounts of manufacturing space were reserved, and sometimes double-booked, by pharma corporations with contract manufacturers. Pfizer, Moderna, and AstraZeneca have all made public announcements about substantial collaborations with CDMOs like Emergent Biosolutions, Catalent, and Lonza, among others to cover major market share. Furthermore, the increased promise of innovation in CDMOs will in the near future promise new opportunities for the growth of market participants in the contract development and manufacturing organizations (CDMOs) market.
In terms of revenue, contract development and manufacturing organizations (CDMOs) market was valued at US$ 159.06 Bn in 2020 growing at a CAGR of 8% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Contract Development and Manufacturing Organizations (CDMOs) Market Revenue & Forecast, (US$ Million), 2015 – 2029
Services Outlook:
Based on services, the global contract development and manufacturing organizations (CDMOs) market has been primarily segmented into development services, analytical research services, clinical & commercial manufacturing, project management, supply chain management & logistics services, regulatory services, and others. Development services is categorised into process and chemical development, analytical development, formulation development, and others. Drug development services dominate the global market in 2020. The pharmaceutical industry's increased spending on process and chemical development, as well as analytical and formulation development, is likely to further contribute towards the segment’s growth over the forecast period.
Application Outlook:
Based on application, the global contract development and manufacturing organizations (CDMOs) market has been classified into drug substance, drug products, cell & gene therapy, and others. Drug substance is further segmented into active pharmaceutical ingredients (API), intermediates, and others. Among these, drug substance segment accounted for the highest market share in 2020. The growing number of biologics APIs in the pipeline stage, as well as the increased use of active pharmaceutical ingredients (API) biologics and Intermediates into a variety of therapies, are expected to fuel API manufacturing segment growth over the projection period.
Organization Size Outlook:
Based on organization size, the global contract development and manufacturing organizations (CDMOs) market has been bifurcated into small and medium enterprises, and large enterprises. Small and medium enterprises is expected to be the fastest growing segment over the forecast period owing to increasing investment by the SMEs into niche pharmaceutical and research sectors, which most essentially caters to the end user requirement.
End Users Outlook:
On the basis of end users, the global contract development and manufacturing organizations (CDMOs) market has been classified into pharmaceutical companies, biotechnology companies, and others. Pharmaceutical companies segment held a significant market share in 2020. With the advent of new technologies, more efficient manufacturing processes, and increased investment flow in the pharmaceutical industry has led to massive transformation in the sector, which is positively impacting market growth. The segment is anticipated to retain its market share over the period of next eight years.
Region Outlook:
Asia Pacific region is estimated to witness fastest growth rate in the global contract development and manufacturing organizations (CDMOs) market over the forecast period. The growing need for robust procedures and production technologies that have proven highly effective in meeting regulatory standards is the primary reason driving CDMO’s growth in the pharmaceutical industry in the Asia-Pacific region. Also, presence of major growing economies in this region such as China, Korea, and India is expected to drive the Asia pacific growth over the forecast period. Increasing investment in the pharmaceutical industry in the Asia pacific region contribute to the market growth. For example, Celltrion, a bio similar manufacturer from South Korea, announced in January 2020 to invest USD 514 million over five years in its new plant in Wuhan, which will be China's largest biologics factory with a capacity of 120,000 liters. The new facility will research and produce its own biologics for the local market, as well as undertake contract work for China's growing biotech industry.
Competitive Landscape Outlook:
The report provides both, qualitative and quantitative research of contract development and manufacturing organizations (CDMOs) market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the contract development and manufacturing organizations (CDMOs) market are:
- Adaptalogix
- AGC Biologics
- Ardena Holding NV
- Catalent, Inc
- CordenPharma International
- Eurofins Scientific
- FAMAR Health Care Services
- Fujifilm Diosynth Biotechnologies
- KBI Biopharma
- Lonza
- mAbxience
- Merck KGaA
- Pfizer Inc.
- Recipharm AB
- Shanghai ChemPartner
- Siegfried Holding AG
- SK biotek
- Thermo Fisher Scientific Inc.
- Other Market Participants
Global Contract Development and Manufacturing Organizations (CDMOs) Market:
- By Services
- Development Services
- Process and Chemical Development
- Analytical Development
- Formulation Development
- Others
- Analytical Research Services
- Clinical & Commercial Manufacturing
- Project Management
- Supply Chain Management & Logistics Services
- Regulatory Services
- Others
- Development Services
- By Application
- Drug Substance
- Active Pharmaceutical Ingredients (API)
- Intermediates
- Others
- Drug Products
- Oral Solids
- Tablets
- Capsules
- Mini-tablets
- Powder
- Others
- Semi-solid
- Creams
- Ointments
- Gels
- Others
- Liquid
- Inhalation
- Sterile
- Others
- Oral Solids
- Cell & Gene Therapy
- Others
- Drug Substance
- By Organization Size
- Small and Medium Enterprises
- Large Enterprises
- By End Users
- Pharmaceutical Companies
- Biotechnology Companies
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2019
1.2.2. Base Year: 2020
1.2.3. Forecast Years: 2021 – 2029
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Contract Development and Manufacturing Organizations (CDMOs) Market
6.
Market
Synopsis: Contract Development and
Manufacturing Organizations (CDMOs) Market
7.
Contract
Development and Manufacturing Organizations (CDMOs) Market Analysis:
Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in Contract Development and
Manufacturing Organizations (CDMOs) Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Contract Development and Manufacturing Organizations (CDMOs) Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Contract Development
and Manufacturing Organizations (CDMOs) Market
8.
Global
Contract Development and Manufacturing Organizations (CDMOs) Market Analysis
and Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn)
8.2. Global Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Services
8.2.1. Development Services (Definition, Market
Estimation and Penetration, 2015 - 2020, Market Estimation (2015 - 2020),
Market Forecast (2021 - 2029), Compound Annual Growth Rate (CAGR), Regional
Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin
America) and Information on Process and Chemical Development, Analytical
Development, Formulation Development, Others)
8.2.1.1.
Process
and Chemical Development
8.2.1.2.
Analytical
Development
8.2.1.3.
Formulation
Development
8.2.1.4.
Others
8.2.2. Analytical Research Services
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.2.3.
Market
Forecast, 2021 - 2029
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2020
8.2.2.5.1.2. Market Forecast, 2021 - 2029
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2020
8.2.2.5.2.2. Market Forecast, 2021 - 2029
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2020
8.2.2.5.3.2. Market Forecast, 2021 - 2029
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2020
8.2.2.5.4.2. Market Forecast, 2021 - 2029
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2020
8.2.2.5.5.2. Market Forecast, 2021 - 2029
8.2.3. Clinical and Commercial Manufacturing
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.3.3.
Market
Forecast, 2021 - 2029
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2020
8.2.3.5.1.2. Market Forecast, 2021 - 2029
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2020
8.2.3.5.2.2. Market Forecast, 2021 - 2029
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2020
8.2.3.5.3.2. Market Forecast, 2021 - 2029
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2020
8.2.3.5.4.2. Market Forecast, 2021 - 2029
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2020
8.2.3.5.5.2. Market Forecast, 2021 - 2029
8.2.4. Project Management
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.4.3.
Market
Forecast, 2021 - 2029
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2020
8.2.4.5.1.2. Market Forecast, 2021 - 2029
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2020
8.2.4.5.2.2. Market Forecast, 2021 - 2029
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2020
8.2.4.5.3.2. Market Forecast, 2021 - 2029
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2020
8.2.4.5.4.2. Market Forecast, 2021 - 2029
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2020
8.2.4.5.5.2. Market Forecast, 2021 - 2029
8.2.5. Supply Chain Management and Logistics
Services
8.2.5.1.
Definition
8.2.5.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.5.3.
Market
Forecast, 2021 - 2029
8.2.5.4.
Compound
Annual Growth Rate (CAGR)
8.2.5.5.
Regional
Bifurcation
8.2.5.5.1.
North
America
8.2.5.5.1.1. Market Estimation, 2015 - 2020
8.2.5.5.1.2. Market Forecast, 2021 - 2029
8.2.5.5.2.
Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2020
8.2.5.5.2.2. Market Forecast, 2021 - 2029
8.2.5.5.3.
Asia
Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2020
8.2.5.5.3.2. Market Forecast, 2021 - 2029
8.2.5.5.4.
Middle
East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2020
8.2.5.5.4.2. Market Forecast, 2021 - 2029
8.2.5.5.5.
Latin
America
8.2.5.5.5.1. Market Estimation, 2015 - 2020
8.2.5.5.5.2. Market Forecast, 2021 - 2029
8.2.6. Regulatory Services
8.2.6.1.
Definition
8.2.6.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.6.3.
Market
Forecast, 2021 - 2029
8.2.6.4.
Compound
Annual Growth Rate (CAGR)
8.2.6.5.
Regional
Bifurcation
8.2.6.5.1.
North
America
8.2.6.5.1.1. Market Estimation, 2015 - 2020
8.2.6.5.1.2. Market Forecast, 2021 - 2029
8.2.6.5.2.
Europe
8.2.6.5.2.1. Market Estimation, 2015 - 2020
8.2.6.5.2.2. Market Forecast, 2021 - 2029
8.2.6.5.3.
Asia
Pacific
8.2.6.5.3.1. Market Estimation, 2015 - 2020
8.2.6.5.3.2. Market Forecast, 2021 - 2029
8.2.6.5.4.
Middle
East and Africa
8.2.6.5.4.1. Market Estimation, 2015 - 2020
8.2.6.5.4.2. Market Forecast, 2021 - 2029
8.2.6.5.5.
Latin
America
8.2.6.5.5.1. Market Estimation, 2015 - 2020
8.2.6.5.5.2. Market Forecast, 2021 - 2029
8.2.7. Others
8.2.7.1.
Definition
8.2.7.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.7.3.
Market
Forecast, 2021 - 2029
8.2.7.4.
Compound
Annual Growth Rate (CAGR)
8.2.7.5.
Regional
Bifurcation
8.2.7.5.1.
North
America
8.2.7.5.1.1. Market Estimation, 2015 - 2020
8.2.7.5.1.2. Market Forecast, 2021 - 2029
8.2.7.5.2.
Europe
8.2.7.5.2.1. Market Estimation, 2015 - 2020
8.2.7.5.2.2. Market Forecast, 2021 - 2029
8.2.7.5.3.
Asia
Pacific
8.2.7.5.3.1. Market Estimation, 2015 - 2020
8.2.7.5.3.2. Market Forecast, 2021 - 2029
8.2.7.5.4.
Middle
East and Africa
8.2.7.5.4.1. Market Estimation, 2015 - 2020
8.2.7.5.4.2. Market Forecast, 2021 - 2029
8.2.7.5.5.
Latin
America
8.2.7.5.5.1. Market Estimation, 2015 - 2020
8.2.7.5.5.2. Market Forecast, 2021 - 2029
8.3. Key Segment for Channeling Investments
8.3.1. By Services
9.
Global
Contract Development and Manufacturing Organizations (CDMOs) Market Analysis
and Forecasts, 2021 – 2029
9.1. Overview
9.2. Global Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Application
9.2.1. Drug Substance (Definition, Market Estimation
and Penetration, 2015 - 2020, Market Estimation (2015 - 2020), Market Forecast
(2021 - 2029), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North
America, Europe, Asia Pacific, Middle East and Africa, Latin America) and
Information on Active Pharmaceutical Ingredients (API), Intermediates, Others)
9.2.1.1.
Active
Pharmaceutical Ingredients (API)
9.2.1.2.
Intermediates
9.2.1.3.
Others
9.2.2. Drug Products (Definition, Market Estimation
and Penetration, 2015 - 2020, Market Estimation (2015 - 2020), Market Forecast
(2021 - 2029), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North
America, Europe, Asia Pacific, Middle East and Africa, Latin America) and
Information on Oral Solids, Semi-solid, Liquid, Inhalation, Sterile, Others)
9.2.2.1.
Oral
Solids
9.2.2.1.1.
Tablets
9.2.2.1.2.
Capsules
9.2.2.1.3.
Mini-tablets
9.2.2.1.4.
Powder
9.2.2.1.5.
Others
9.2.2.2.
Semi-solid
9.2.2.2.1.
Creams
9.2.2.2.2.
Ointments
9.2.2.2.3.
Gels
9.2.2.2.4.
Others
9.2.2.3.
Liquid
9.2.2.4.
Inhalation
9.2.2.5.
Sterile
9.2.2.6.
Others
9.2.3. Cell and Gene Therapy
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.3.3.
Market
Forecast, 2021 - 2029
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2020
9.2.3.5.1.2. Market Forecast, 2021 - 2029
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2020
9.2.3.5.2.2. Market Forecast, 2021 - 2029
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2020
9.2.3.5.3.2. Market Forecast, 2021 - 2029
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2020
9.2.3.5.4.2. Market Forecast, 2021 - 2029
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2020
9.2.3.5.5.2. Market Forecast, 2021 - 2029
9.2.4. Others
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.4.3.
Market
Forecast, 2021 - 2029
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2020
9.2.4.5.1.2. Market Forecast, 2021 - 2029
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2020
9.2.4.5.2.2. Market Forecast, 2021 - 2029
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2020
9.2.4.5.3.2. Market Forecast, 2021 - 2029
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2020
9.2.4.5.4.2. Market Forecast, 2021 - 2029
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2020
9.2.4.5.5.2. Market Forecast, 2021 - 2029
9.3. Key Segment for Channeling Investments
9.3.1. By Application
10. Global Contract Development and
Manufacturing Organizations (CDMOs) Market Analysis and Forecasts, 2021 – 2029
10.1. Overview
10.2. Global Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization
Size
10.2.1. Small and Medium Enterprises
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 -
2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 - 2020
10.2.1.5.1.2. Market Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2020
10.2.1.5.2.2. Market Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2020
10.2.1.5.3.2. Market Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2020
10.2.1.5.4.2. Market Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 - 2020
10.2.1.5.5.2. Market Forecast, 2021 - 2029
10.2.2. Large Enterprises
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 -
2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 - 2020
10.2.2.5.1.2. Market Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2020
10.2.2.5.2.2. Market Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2020
10.2.2.5.3.2. Market Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2020
10.2.2.5.4.2. Market Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 - 2020
10.2.2.5.5.2. Market Forecast, 2021 - 2029
10.3. Key Segment for Channeling Investments
10.3.1. By Organization Size
11. Global Contract Development and
Manufacturing Organizations (CDMOs) Market Analysis and Forecasts, 2021 – 2029
11.1. Overview
11.2. Global Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By End Users
11.2.1. Pharmaceutical Companies
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 -
2020
11.2.1.3. Market Forecast, 2021 - 2029
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market Estimation, 2015 - 2020
11.2.1.5.1.2. Market Forecast, 2021 - 2029
11.2.1.5.2. Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2020
11.2.1.5.2.2. Market Forecast, 2021 - 2029
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2020
11.2.1.5.3.2. Market Forecast, 2021 - 2029
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2020
11.2.1.5.4.2. Market Forecast, 2021 - 2029
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market Estimation, 2015 - 2020
11.2.1.5.5.2. Market Forecast, 2021 - 2029
11.2.2. Biotechnology Companies
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 -
2020
11.2.2.3. Market Forecast, 2021 - 2029
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market Estimation, 2015 - 2020
11.2.2.5.1.2. Market Forecast, 2021 - 2029
11.2.2.5.2. Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2020
11.2.2.5.2.2. Market Forecast, 2021 - 2029
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2020
11.2.2.5.3.2. Market Forecast, 2021 - 2029
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2020
11.2.2.5.4.2. Market Forecast, 2021 - 2029
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market Estimation, 2015 - 2020
11.2.2.5.5.2. Market Forecast, 2021 - 2029
11.2.3. Others
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 -
2020
11.2.3.3. Market Forecast, 2021 - 2029
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market Estimation, 2015 - 2020
11.2.3.5.1.2. Market Forecast, 2021 - 2029
11.2.3.5.2. Europe
11.2.3.5.2.1. Market Estimation, 2015 - 2020
11.2.3.5.2.2. Market Forecast, 2021 - 2029
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market Estimation, 2015 - 2020
11.2.3.5.3.2. Market Forecast, 2021 - 2029
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market Estimation, 2015 - 2020
11.2.3.5.4.2. Market Forecast, 2021 - 2029
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market Estimation, 2015 - 2020
11.2.3.5.5.2. Market Forecast, 2021 - 2029
11.3. Key Segment for Channeling Investments
11.3.1. By End Users
12. North America Contract Development and
Manufacturing Organizations (CDMOs) Market Analysis and Forecasts, 2021 - 2029
12.1. Overview
12.1.1. North America Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn)
12.2. North America Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Services
12.2.1. Development Services
12.2.1.1. Process and Chemical Development
12.2.1.2. Analytical Development
12.2.1.3. Formulation Development
12.2.1.4. Others
12.2.2. Analytical Research Services
12.2.3. Clinical and Commercial Manufacturing
12.2.4. Project Management
12.2.5. Supply Chain Management and Logistics
Services
12.2.6. Regulatory Services
12.2.7. Others
12.3. North America Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Application
12.3.1. Drug Substance
12.3.1.1. Active Pharmaceutical Ingredients (API)
12.3.1.2. Intermediates
12.3.1.3. Others
12.3.2. Drug Products
12.3.2.1. Oral Solids
12.3.2.1.1. Tablets
12.3.2.1.2. Capsules
12.3.2.1.3. Mini-tablets
12.3.2.1.4. Powder
12.3.2.1.5. Others
12.3.2.2. Semi-solid
12.3.2.2.1. Creams
12.3.2.2.2. Ointments
12.3.2.2.3. Gels
12.3.2.2.4. Others
12.3.2.3. Liquid
12.3.2.4. Inhalation
12.3.2.5. Sterile
12.3.2.6. Others
12.3.3. Cell and Gene Therapy
12.3.4. Others
12.4. North America Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization
Size
12.4.1. Small and Medium Enterprises
12.4.2. Large Enterprises
12.5. North America Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
End Users
12.5.1. Pharmaceutical Companies
12.5.2. Biotechnology Companies
12.5.3. Others
12.6. North America Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Country
12.6.1. U.S
12.6.1.1. U.S Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Services
12.6.1.1.1. Development Services
12.6.1.1.1.1. Process and Chemical Development
12.6.1.1.1.2. Analytical Development
12.6.1.1.1.3. Formulation Development
12.6.1.1.1.4. Others
12.6.1.1.2. Analytical Research Services
12.6.1.1.3. Clinical and Commercial Manufacturing
12.6.1.1.4. Project Management
12.6.1.1.5. Supply Chain Management and Logistics
Services
12.6.1.1.6. Regulatory Services
12.6.1.1.7. Others
12.6.1.2. U.S Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Application
12.6.1.2.1. Drug Substance
12.6.1.2.1.1. Active Pharmaceutical Ingredients (API)
12.6.1.2.1.2. Intermediates
12.6.1.2.1.3. Others
12.6.1.2.2. Drug Products
12.6.1.2.2.1. Oral Solids
12.6.1.2.2.1.1. Tablets
12.6.1.2.2.1.2. Capsules
12.6.1.2.2.1.3. Mini-tablets
12.6.1.2.2.1.4. Powder
12.6.1.2.2.1.5. Others
12.6.1.2.2.2. Semi-solid
12.6.1.2.2.2.1. Creams
12.6.1.2.2.2.2. Ointments
12.6.1.2.2.2.3. Gels
12.6.1.2.2.2.4. Others
12.6.1.2.2.3. Liquid
12.6.1.2.2.4. Inhalation
12.6.1.2.2.5. Sterile
12.6.1.2.2.6. Others
12.6.1.2.3. Cell and Gene Therapy
12.6.1.2.4. Others
12.6.1.3. U.S Contract Development and Manufacturing Organizations
(CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization Size
12.6.1.3.1. Small and Medium Enterprises
12.6.1.3.2. Large Enterprises
12.6.1.4. U.S Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.1.4.1. Pharmaceutical Companies
12.6.1.4.2. Biotechnology Companies
12.6.1.4.3. Others
12.6.2. Canada
12.6.2.1. Canada Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Services
12.6.2.1.1. Development Services
12.6.2.1.1.1. Process and Chemical Development
12.6.2.1.1.2. Analytical Development
12.6.2.1.1.3. Formulation Development
12.6.2.1.1.4. Others
12.6.2.1.2. Analytical Research Services
12.6.2.1.3. Clinical and Commercial Manufacturing
12.6.2.1.4. Project Management
12.6.2.1.5. Supply Chain Management and Logistics
Services
12.6.2.1.6. Regulatory Services
12.6.2.1.7. Others
12.6.2.2. Canada Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Application
12.6.2.2.1. Drug Substance
12.6.2.2.1.1. Active Pharmaceutical Ingredients (API)
12.6.2.2.1.2. Intermediates
12.6.2.2.1.3. Others
12.6.2.2.2. Drug Products
12.6.2.2.2.1. Oral Solids
12.6.2.2.2.1.1. Tablets
12.6.2.2.2.1.2. Capsules
12.6.2.2.2.1.3. Mini-tablets
12.6.2.2.2.1.4. Powder
12.6.2.2.2.1.5. Others
12.6.2.2.2.2. Semi-solid
12.6.2.2.2.2.1. Creams
12.6.2.2.2.2.2. Ointments
12.6.2.2.2.2.3. Gels
12.6.2.2.2.2.4. Others
12.6.2.2.2.3. Liquid
12.6.2.2.2.4. Inhalation
12.6.2.2.2.5. Sterile
12.6.2.2.2.6. Others
12.6.2.2.3. Cell and Gene Therapy
12.6.2.2.4. Others
12.6.2.3. Canada Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization
Size
12.6.2.3.1. Small and Medium Enterprises
12.6.2.3.2. Large Enterprises
12.6.2.4. Canada Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.2.4.1. Pharmaceutical Companies
12.6.2.4.2. Biotechnology Companies
12.6.2.4.3. Others
12.6.3. Mexico
12.6.3.1. Mexico Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Services
12.6.3.1.1. Development Services
12.6.3.1.1.1. Process and Chemical Development
12.6.3.1.1.2. Analytical Development
12.6.3.1.1.3. Formulation Development
12.6.3.1.1.4. Others
12.6.3.1.2. Analytical Research Services
12.6.3.1.3. Clinical and Commercial Manufacturing
12.6.3.1.4. Project Management
12.6.3.1.5. Supply Chain Management and Logistics
Services
12.6.3.1.6. Regulatory Services
12.6.3.1.7. Others
12.6.3.2. Mexico Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Application
12.6.3.2.1. Drug Substance
12.6.3.2.1.1. Active Pharmaceutical Ingredients (API)
12.6.3.2.1.2. Intermediates
12.6.3.2.1.3. Others
12.6.3.2.2. Drug Products
12.6.3.2.2.1. Oral Solids
12.6.3.2.2.1.1. Tablets
12.6.3.2.2.1.2. Capsules
12.6.3.2.2.1.3. Mini-tablets
12.6.3.2.2.1.4. Powder
12.6.3.2.2.1.5. Others
12.6.3.2.2.2. Semi-solid
12.6.3.2.2.2.1. Creams
12.6.3.2.2.2.2. Ointments
12.6.3.2.2.2.3. Gels
12.6.3.2.2.2.4. Others
12.6.3.2.2.3. Liquid
12.6.3.2.2.4. Inhalation
12.6.3.2.2.5. Sterile
12.6.3.2.2.6. Others
12.6.3.2.3. Cell and Gene Therapy
12.6.3.2.4. Others
12.6.3.3. Mexico Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization
Size
12.6.3.3.1. Small and Medium Enterprises
12.6.3.3.2. Large Enterprises
12.6.3.4. Mexico Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.3.4.1. Pharmaceutical Companies
12.6.3.4.2. Biotechnology Companies
12.6.3.4.3. Others
12.6.4. Rest of North America
12.6.4.1. Rest of North America Contract Development
and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts,
By Services
12.6.4.1.1. Development Services
12.6.4.1.1.1. Process and Chemical Development
12.6.4.1.1.2. Analytical Development
12.6.4.1.1.3. Formulation Development
12.6.4.1.1.4. Others
12.6.4.1.2. Analytical Research Services
12.6.4.1.3. Clinical and Commercial Manufacturing
12.6.4.1.4. Project Management
12.6.4.1.5. Supply Chain Management and Logistics
Services
12.6.4.1.6. Regulatory Services
12.6.4.1.7. Others
12.6.4.2. Rest of North America Contract Development
and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts,
By Application
12.6.4.2.1. Drug Substance
12.6.4.2.1.1. Active Pharmaceutical Ingredients (API)
12.6.4.2.1.2. Intermediates
12.6.4.2.1.3. Others
12.6.4.2.2. Drug Products
12.6.4.2.2.1. Oral Solids
12.6.4.2.2.1.1. Tablets
12.6.4.2.2.1.2. Capsules
12.6.4.2.2.1.3. Mini-tablets
12.6.4.2.2.1.4. Powder
12.6.4.2.2.1.5. Others
12.6.4.2.2.2. Semi-solid
12.6.4.2.2.2.1. Creams
12.6.4.2.2.2.2. Ointments
12.6.4.2.2.2.3. Gels
12.6.4.2.2.2.4. Others
12.6.4.2.2.3. Liquid
12.6.4.2.2.4. Inhalation
12.6.4.2.2.5. Sterile
12.6.4.2.2.6. Others
12.6.4.2.3. Cell and Gene Therapy
12.6.4.2.4. Others
12.6.4.3. Rest of North America Contract Development
and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts,
By Organization Size
12.6.4.3.1. Small and Medium Enterprises
12.6.4.3.2. Large Enterprises
12.6.4.4. Rest of North America Contract Development
and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts,
By End Users
12.6.4.4.1. Pharmaceutical Companies
12.6.4.4.2. Biotechnology Companies
12.6.4.4.3. Others
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Services
12.7.3. By Application
12.7.4. By Organization Size
12.7.5. By End Users
13. Europe Contract Development and
Manufacturing Organizations (CDMOs) Market Analysis and Forecasts, 2021 - 2029
13.1. Overview
13.1.1. Europe Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn)
13.2. Europe Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Services
13.2.1. Development Services
13.2.1.1. Process and Chemical Development
13.2.1.2. Analytical Development
13.2.1.3. Formulation Development
13.2.1.4. Others
13.2.2. Analytical Research Services
13.2.3. Clinical and Commercial Manufacturing
13.2.4. Project Management
13.2.5. Supply Chain Management and Logistics
Services
13.2.6. Regulatory Services
13.2.7. Others
13.3. Europe Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Application
13.3.1. Drug Substance
13.3.1.1. Active Pharmaceutical Ingredients (API)
13.3.1.2. Intermediates
13.3.1.3. Others
13.3.2. Drug Products
13.3.2.1. Oral Solids
13.3.2.1.1. Tablets
13.3.2.1.2. Capsules
13.3.2.1.3. Mini-tablets
13.3.2.1.4. Powder
13.3.2.1.5. Others
13.3.2.2. Semi-solid
13.3.2.2.1. Creams
13.3.2.2.2. Ointments
13.3.2.2.3. Gels
13.3.2.2.4. Others
13.3.2.3. Liquid
13.3.2.4. Inhalation
13.3.2.5. Sterile
13.3.2.6. Others
13.3.3. Cell and Gene Therapy
13.3.4. Others
13.4. Europe Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization
Size
13.4.1. Small and Medium Enterprises
13.4.2. Large Enterprises
13.5. Europe Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.1. Pharmaceutical Companies
13.5.2. Biotechnology Companies
13.5.3. Others
13.6. Europe Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Services
13.6.1.1.1. Development Services
13.6.1.1.1.1. Process and Chemical Development
13.6.1.1.1.2. Analytical Development
13.6.1.1.1.3. Formulation Development
13.6.1.1.1.4. Others
13.6.1.1.2. Analytical Research Services
13.6.1.1.3. Clinical and Commercial Manufacturing
13.6.1.1.4. Project Management
13.6.1.1.5. Supply Chain Management and Logistics
Services
13.6.1.1.6. Regulatory Services
13.6.1.1.7. Others
13.6.1.2. France Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Application
13.6.1.2.1. Drug Substance
13.6.1.2.1.1. Active Pharmaceutical Ingredients (API)
13.6.1.2.1.2. Intermediates
13.6.1.2.1.3. Others
13.6.1.2.2. Drug Products
13.6.1.2.2.1. Oral Solids
13.6.1.2.2.1.1. Tablets
13.6.1.2.2.1.2. Capsules
13.6.1.2.2.1.3. Mini-tablets
13.6.1.2.2.1.4. Powder
13.6.1.2.2.1.5. Others
13.6.1.2.2.2. Semi-solid
13.6.1.2.2.2.1. Creams
13.6.1.2.2.2.2. Ointments
13.6.1.2.2.2.3. Gels
13.6.1.2.2.2.4. Others
13.6.1.2.2.3. Liquid
13.6.1.2.2.4. Inhalation
13.6.1.2.2.5. Sterile
13.6.1.2.2.6. Others
13.6.1.2.3. Cell and Gene Therapy
13.6.1.2.4. Others
13.6.1.3. France Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization
Size
13.6.1.3.1. Small and Medium Enterprises
13.6.1.3.2. Large Enterprises
13.6.1.4. France Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.1.4.1. Pharmaceutical Companies
13.6.1.4.2. Biotechnology Companies
13.6.1.4.3. Others
13.6.2. The UK
13.6.2.1. The UK Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Services
13.6.2.1.1. Development Services
13.6.2.1.1.1. Process and Chemical Development
13.6.2.1.1.2. Analytical Development
13.6.2.1.1.3. Formulation Development
13.6.2.1.1.4. Others
13.6.2.1.2. Analytical Research Services
13.6.2.1.3. Clinical and Commercial Manufacturing
13.6.2.1.4. Project Management
13.6.2.1.5. Supply Chain Management and Logistics Services
13.6.2.1.6. Regulatory Services
13.6.2.1.7. Others
13.6.2.2. The UK Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Application
13.6.2.2.1. Drug Substance
13.6.2.2.1.1. Active Pharmaceutical Ingredients (API)
13.6.2.2.1.2. Intermediates
13.6.2.2.1.3. Others
13.6.2.2.2. Drug Products
13.6.2.2.2.1. Oral Solids
13.6.2.2.2.1.1. Tablets
13.6.2.2.2.1.2. Capsules
13.6.2.2.2.1.3. Mini-tablets
13.6.2.2.2.1.4. Powder
13.6.2.2.2.1.5. Others
13.6.2.2.2.2. Semi-solid
13.6.2.2.2.2.1. Creams
13.6.2.2.2.2.2. Ointments
13.6.2.2.2.2.3. Gels
13.6.2.2.2.2.4. Others
13.6.2.2.2.3. Liquid
13.6.2.2.2.4. Inhalation
13.6.2.2.2.5. Sterile
13.6.2.2.2.6. Others
13.6.2.2.3. Cell and Gene Therapy
13.6.2.2.4. Others
13.6.2.3. The UK Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization
Size
13.6.2.3.1. Small and Medium Enterprises
13.6.2.3.2. Large Enterprises
13.6.2.4. The UK Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.2.4.1. Pharmaceutical Companies
13.6.2.4.2. Biotechnology Companies
13.6.2.4.3. Others
13.6.3. Spain
13.6.3.1. Spain Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Services
13.6.3.1.1. Development Services
13.6.3.1.1.1. Process and Chemical Development
13.6.3.1.1.2. Analytical Development
13.6.3.1.1.3. Formulation Development
13.6.3.1.1.4. Others
13.6.3.1.2. Analytical Research Services
13.6.3.1.3. Clinical and Commercial Manufacturing
13.6.3.1.4. Project Management
13.6.3.1.5. Supply Chain Management and Logistics
Services
13.6.3.1.6. Regulatory Services
13.6.3.1.7. Others
13.6.3.2. Spain Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Application
13.6.3.2.1. Drug Substance
13.6.3.2.1.1. Active Pharmaceutical Ingredients (API)
13.6.3.2.1.2. Intermediates
13.6.3.2.1.3. Others
13.6.3.2.2. Drug Products
13.6.3.2.2.1. Oral Solids
13.6.3.2.2.1.1. Tablets
13.6.3.2.2.1.2. Capsules
13.6.3.2.2.1.3. Mini-tablets
13.6.3.2.2.1.4. Powder
13.6.3.2.2.1.5. Others
13.6.3.2.2.2. Semi-solid
13.6.3.2.2.2.1. Creams
13.6.3.2.2.2.2. Ointments
13.6.3.2.2.2.3. Gels
13.6.3.2.2.2.4. Others
13.6.3.2.2.3. Liquid
13.6.3.2.2.4. Inhalation
13.6.3.2.2.5. Sterile
13.6.3.2.2.6. Others
13.6.3.2.3. Cell and Gene Therapy
13.6.3.2.4. Others
13.6.3.3. Spain Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization
Size
13.6.3.3.1. Small and Medium Enterprises
13.6.3.3.2. Large Enterprises
13.6.3.4. Spain Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.3.4.1. Pharmaceutical Companies
13.6.3.4.2. Biotechnology Companies
13.6.3.4.3. Others
13.6.4. Germany
13.6.4.1. Germany Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Services
13.6.4.1.1. Development Services
13.6.4.1.1.1. Process and Chemical Development
13.6.4.1.1.2. Analytical Development
13.6.4.1.1.3. Formulation Development
13.6.4.1.1.4. Others
13.6.4.1.2. Analytical Research Services
13.6.4.1.3. Clinical and Commercial Manufacturing
13.6.4.1.4. Project Management
13.6.4.1.5. Supply Chain Management and Logistics
Services
13.6.4.1.6. Regulatory Services
13.6.4.1.7. Others
13.6.4.2. Germany Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.4.2.1. Drug Substance
13.6.4.2.1.1. Active Pharmaceutical Ingredients (API)
13.6.4.2.1.2. Intermediates
13.6.4.2.1.3. Others
13.6.4.2.2. Drug Products
13.6.4.2.2.1. Oral Solids
13.6.4.2.2.1.1. Tablets
13.6.4.2.2.1.2. Capsules
13.6.4.2.2.1.3. Mini-tablets
13.6.4.2.2.1.4. Powder
13.6.4.2.2.1.5. Others
13.6.4.2.2.2. Semi-solid
13.6.4.2.2.2.1. Creams
13.6.4.2.2.2.2. Ointments
13.6.4.2.2.2.3. Gels
13.6.4.2.2.2.4. Others
13.6.4.2.2.3. Liquid
13.6.4.2.2.4. Inhalation
13.6.4.2.2.5. Sterile
13.6.4.2.2.6. Others
13.6.4.2.3. Cell and Gene Therapy
13.6.4.2.4. Others
13.6.4.3. Germany Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Organization Size
13.6.4.3.1. Small and Medium Enterprises
13.6.4.3.2. Large Enterprises
13.6.4.4. Germany Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
End Users
13.6.4.4.1. Pharmaceutical Companies
13.6.4.4.2. Biotechnology Companies
13.6.4.4.3. Others
13.6.5. Italy
13.6.5.1. Italy Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Services
13.6.5.1.1. Development Services
13.6.5.1.1.1. Process and Chemical Development
13.6.5.1.1.2. Analytical Development
13.6.5.1.1.3. Formulation Development
13.6.5.1.1.4. Others
13.6.5.1.2. Analytical Research Services
13.6.5.1.3. Clinical and Commercial Manufacturing
13.6.5.1.4. Project Management
13.6.5.1.5. Supply Chain Management and Logistics
Services
13.6.5.1.6. Regulatory Services
13.6.5.1.7. Others
13.6.5.2. Italy Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Application
13.6.5.2.1. Drug Substance
13.6.5.2.1.1. Active Pharmaceutical Ingredients (API)
13.6.5.2.1.2. Intermediates
13.6.5.2.1.3. Others
13.6.5.2.2. Drug Products
13.6.5.2.2.1. Oral Solids
13.6.5.2.2.1.1. Tablets
13.6.5.2.2.1.2. Capsules
13.6.5.2.2.1.3. Mini-tablets
13.6.5.2.2.1.4. Powder
13.6.5.2.2.1.5. Others
13.6.5.2.2.2. Semi-solid
13.6.5.2.2.2.1. Creams
13.6.5.2.2.2.2. Ointments
13.6.5.2.2.2.3. Gels
13.6.5.2.2.2.4. Others
13.6.5.2.2.3. Liquid
13.6.5.2.2.4. Inhalation
13.6.5.2.2.5. Sterile
13.6.5.2.2.6. Others
13.6.5.2.3. Cell and Gene Therapy
13.6.5.2.4. Others
13.6.5.3. Italy Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization
Size
13.6.5.3.1. Small and Medium Enterprises
13.6.5.3.2. Large Enterprises
13.6.5.4. Italy Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.5.4.1. Pharmaceutical Companies
13.6.5.4.2. Biotechnology Companies
13.6.5.4.3. Others
13.6.6. Nordic Countries
13.6.6.1. Nordic Countries Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Services
13.6.6.1.1. Development Services
13.6.6.1.1.1. Process and Chemical Development
13.6.6.1.1.2. Analytical Development
13.6.6.1.1.3. Formulation Development
13.6.6.1.1.4. Others
13.6.6.1.2. Analytical Research Services
13.6.6.1.3. Clinical and Commercial Manufacturing
13.6.6.1.4. Project Management
13.6.6.1.5. Supply Chain Management and Logistics
Services
13.6.6.1.6. Regulatory Services
13.6.6.1.7. Others
13.6.6.2. Nordic Countries Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.6.2.1. Drug Substance
13.6.6.2.1.1. Active Pharmaceutical Ingredients (API)
13.6.6.2.1.2. Intermediates
13.6.6.2.1.3. Others
13.6.6.2.2. Drug Products
13.6.6.2.2.1. Oral Solids
13.6.6.2.2.1.1. Tablets
13.6.6.2.2.1.2. Capsules
13.6.6.2.2.1.3. Mini-tablets
13.6.6.2.2.1.4. Powder
13.6.6.2.2.1.5. Others
13.6.6.2.2.2. Semi-solid
13.6.6.2.2.2.1. Creams
13.6.6.2.2.2.2. Ointments
13.6.6.2.2.2.3. Gels
13.6.6.2.2.2.4. Others
13.6.6.2.2.3. Liquid
13.6.6.2.2.4. Inhalation
13.6.6.2.2.5. Sterile
13.6.6.2.2.6. Others
13.6.6.2.3. Cell and Gene Therapy
13.6.6.2.4. Others
13.6.6.3. Nordic Countries Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization
Size
13.6.6.3.1. Small and Medium Enterprises
13.6.6.3.2. Large Enterprises
13.6.6.4. Nordic Countries Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
End Users
13.6.6.4.1. Pharmaceutical Companies
13.6.6.4.2. Biotechnology Companies
13.6.6.4.3. Others
13.6.6.5. Nordic Countries Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux Union
13.6.7.1. Benelux Union Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Services
13.6.7.1.1. Development Services
13.6.7.1.1.1. Process and Chemical Development
13.6.7.1.1.2. Analytical Development
13.6.7.1.1.3. Formulation Development
13.6.7.1.1.4. Others
13.6.7.1.2. Analytical Research Services
13.6.7.1.3. Clinical and Commercial Manufacturing
13.6.7.1.4. Project Management
13.6.7.1.5. Supply Chain Management and Logistics
Services
13.6.7.1.6. Regulatory Services
13.6.7.1.7. Others
13.6.7.2. Benelux Union Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.7.2.1. Drug Substance
13.6.7.2.1.1. Active Pharmaceutical Ingredients (API)
13.6.7.2.1.2. Intermediates
13.6.7.2.1.3. Others
13.6.7.2.2. Drug Products
13.6.7.2.2.1. Oral Solids
13.6.7.2.2.1.1. Tablets
13.6.7.2.2.1.2. Capsules
13.6.7.2.2.1.3. Mini-tablets
13.6.7.2.2.1.4. Powder
13.6.7.2.2.1.5. Others
13.6.7.2.2.2. Semi-solid
13.6.7.2.2.2.1. Creams
13.6.7.2.2.2.2. Ointments
13.6.7.2.2.2.3. Gels
13.6.7.2.2.2.4. Others
13.6.7.2.2.3. Liquid
13.6.7.2.2.4. Inhalation
13.6.7.2.2.5. Sterile
13.6.7.2.2.6. Others
13.6.7.2.3. Cell and Gene Therapy
13.6.7.2.4. Others
13.6.7.3. Benelux Union Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Organization Size
13.6.7.3.1. Small and Medium Enterprises
13.6.7.3.2. Large Enterprises
13.6.7.4. Benelux Union Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
End Users
13.6.7.4.1. Pharmaceutical Companies
13.6.7.4.2. Biotechnology Companies
13.6.7.4.3. Others
13.6.7.5. Benelux Union Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of Europe
13.6.8.1. Rest of Europe Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Services
13.6.8.1.1. Development Services
13.6.8.1.1.1. Process and Chemical Development
13.6.8.1.1.2. Analytical Development
13.6.8.1.1.3. Formulation Development
13.6.8.1.1.4. Others
13.6.8.1.2. Analytical Research Services
13.6.8.1.3. Clinical and Commercial Manufacturing
13.6.8.1.4. Project Management
13.6.8.1.5. Supply Chain Management and Logistics
Services
13.6.8.1.6. Regulatory Services
13.6.8.1.7. Others
13.6.8.2. Rest of Europe Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.8.2.1. Drug Substance
13.6.8.2.1.1. Active Pharmaceutical Ingredients (API)
13.6.8.2.1.2. Intermediates
13.6.8.2.1.3. Others
13.6.8.2.2. Drug Products
13.6.8.2.2.1. Oral Solids
13.6.8.2.2.1.1. Tablets
13.6.8.2.2.1.2. Capsules
13.6.8.2.2.1.3. Mini-tablets
13.6.8.2.2.1.4. Powder
13.6.8.2.2.1.5. Others
13.6.8.2.2.2. Semi-solid
13.6.8.2.2.2.1. Creams
13.6.8.2.2.2.2. Ointments
13.6.8.2.2.2.3. Gels
13.6.8.2.2.2.4. Others
13.6.8.2.2.3. Liquid
13.6.8.2.2.4. Inhalation
13.6.8.2.2.5. Sterile
13.6.8.2.2.6. Others
13.6.8.2.3. Cell and Gene Therapy
13.6.8.2.4. Others
13.6.8.3. Rest of Europe Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Organization Size
13.6.8.3.1. Small and Medium Enterprises
13.6.8.3.2. Large Enterprises
13.6.8.4. Rest of Europe Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
End Users
13.6.8.4.1. Pharmaceutical Companies
13.6.8.4.2. Biotechnology Companies
13.6.8.4.3. Others
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Services
13.7.3. By Application
13.7.4. By Organization Size
13.7.5. By End Users
14. Asia Pacific Contract Development and
Manufacturing Organizations (CDMOs) Market Analysis and Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Asia Pacific Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn)
14.2. Asia Pacific Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Services
14.2.1. Development Services
14.2.1.1. Process and Chemical Development
14.2.1.2. Analytical Development
14.2.1.3. Formulation Development
14.2.1.4. Others
14.2.2. Analytical Research Services
14.2.3. Clinical and Commercial Manufacturing
14.2.4. Project Management
14.2.5. Supply Chain Management and Logistics
Services
14.2.6. Regulatory Services
14.2.7. Others
14.3. Asia Pacific Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Application
14.3.1. Drug Substance
14.3.1.1. Active Pharmaceutical Ingredients (API)
14.3.1.2. Intermediates
14.3.1.3. Others
14.3.2. Drug Products
14.3.2.1. Oral Solids
14.3.2.1.1. Tablets
14.3.2.1.2. Capsules
14.3.2.1.3. Mini-tablets
14.3.2.1.4. Powder
14.3.2.1.5. Others
14.3.2.2. Semi-solid
14.3.2.2.1. Creams
14.3.2.2.2. Ointments
14.3.2.2.3. Gels
14.3.2.2.4. Others
14.3.2.3. Liquid
14.3.2.4. Inhalation
14.3.2.5. Sterile
14.3.2.6. Others
14.3.3. Cell and Gene Therapy
14.3.4. Others
14.4. Asia Pacific Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization
Size
14.4.1. Small and Medium Enterprises
14.4.2. Large Enterprises
14.5. Asia Pacific Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
End Users
14.5.1. Pharmaceutical Companies
14.5.2. Biotechnology Companies
14.5.3. Others
14.6. Asia Pacific Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.1. China
14.6.1.1. China Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Services
14.6.1.1.1. Development Services
14.6.1.1.1.1. Process and Chemical Development
14.6.1.1.1.2. Analytical Development
14.6.1.1.1.3. Formulation Development
14.6.1.1.1.4. Others
14.6.1.1.2. Analytical Research Services
14.6.1.1.3. Clinical and Commercial Manufacturing
14.6.1.1.4. Project Management
14.6.1.1.5. Supply Chain Management and Logistics
Services
14.6.1.1.6. Regulatory Services
14.6.1.1.7. Others
14.6.1.2. China Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Application
14.6.1.2.1. Drug Substance
14.6.1.2.1.1. Active Pharmaceutical Ingredients (API)
14.6.1.2.1.2. Intermediates
14.6.1.2.1.3. Others
14.6.1.2.2. Drug Products
14.6.1.2.2.1. Oral Solids
14.6.1.2.2.1.1. Tablets
14.6.1.2.2.1.2. Capsules
14.6.1.2.2.1.3. Mini-tablets
14.6.1.2.2.1.4. Powder
14.6.1.2.2.1.5. Others
14.6.1.2.2.2. Semi-solid
14.6.1.2.2.2.1. Creams
14.6.1.2.2.2.2. Ointments
14.6.1.2.2.2.3. Gels
14.6.1.2.2.2.4. Others
14.6.1.2.2.3. Liquid
14.6.1.2.2.4. Inhalation
14.6.1.2.2.5. Sterile
14.6.1.2.2.6. Others
14.6.1.2.3. Cell and Gene Therapy
14.6.1.2.4. Others
14.6.1.3. China Contract Development and Manufacturing Organizations
(CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization Size
14.6.1.3.1. Small and Medium Enterprises
14.6.1.3.2. Large Enterprises
14.6.1.4. China Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.1.4.1. Pharmaceutical Companies
14.6.1.4.2. Biotechnology Companies
14.6.1.4.3. Others
14.6.2. Japan
14.6.2.1. Japan Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Services
14.6.2.1.1. Development Services
14.6.2.1.1.1. Process and Chemical Development
14.6.2.1.1.2. Analytical Development
14.6.2.1.1.3. Formulation Development
14.6.2.1.1.4. Others
14.6.2.1.2. Analytical Research Services
14.6.2.1.3. Clinical and Commercial Manufacturing
14.6.2.1.4. Project Management
14.6.2.1.5. Supply Chain Management and Logistics
Services
14.6.2.1.6. Regulatory Services
14.6.2.1.7. Others
14.6.2.2. Japan Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Application
14.6.2.2.1. Drug Substance
14.6.2.2.1.1. Active Pharmaceutical Ingredients (API)
14.6.2.2.1.2. Intermediates
14.6.2.2.1.3. Others
14.6.2.2.2. Drug Products
14.6.2.2.2.1. Oral Solids
14.6.2.2.2.1.1. Tablets
14.6.2.2.2.1.2. Capsules
14.6.2.2.2.1.3. Mini-tablets
14.6.2.2.2.1.4. Powder
14.6.2.2.2.1.5. Others
14.6.2.2.2.2. Semi-solid
14.6.2.2.2.2.1. Creams
14.6.2.2.2.2.2. Ointments
14.6.2.2.2.2.3. Gels
14.6.2.2.2.2.4. Others
14.6.2.2.2.3. Liquid
14.6.2.2.2.4. Inhalation
14.6.2.2.2.5. Sterile
14.6.2.2.2.6. Others
14.6.2.2.3. Cell and Gene Therapy
14.6.2.2.4. Others
14.6.2.3. Japan Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization
Size
14.6.2.3.1. Small and Medium Enterprises
14.6.2.3.2. Large Enterprises
14.6.2.4. Japan Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.2.4.1. Pharmaceutical Companies
14.6.2.4.2. Biotechnology Companies
14.6.2.4.3. Others
14.6.3. India
14.6.3.1. India Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Services
14.6.3.1.1. Development Services
14.6.3.1.1.1. Process and Chemical Development
14.6.3.1.1.2. Analytical Development
14.6.3.1.1.3. Formulation Development
14.6.3.1.1.4. Others
14.6.3.1.2. Analytical Research Services
14.6.3.1.3. Clinical and Commercial Manufacturing
14.6.3.1.4. Project Management
14.6.3.1.5. Supply Chain Management and Logistics Services
14.6.3.1.6. Regulatory Services
14.6.3.1.7. Others
14.6.3.2. India Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Application
14.6.3.2.1. Drug Substance
14.6.3.2.1.1. Active Pharmaceutical Ingredients (API)
14.6.3.2.1.2. Intermediates
14.6.3.2.1.3. Others
14.6.3.2.2. Drug Products
14.6.3.2.2.1. Oral Solids
14.6.3.2.2.1.1. Tablets
14.6.3.2.2.1.2. Capsules
14.6.3.2.2.1.3. Mini-tablets
14.6.3.2.2.1.4. Powder
14.6.3.2.2.1.5. Others
14.6.3.2.2.2. Semi-solid
14.6.3.2.2.2.1. Creams
14.6.3.2.2.2.2. Ointments
14.6.3.2.2.2.3. Gels
14.6.3.2.2.2.4. Others
14.6.3.2.2.3. Liquid
14.6.3.2.2.4. Inhalation
14.6.3.2.2.5. Sterile
14.6.3.2.2.6. Others
14.6.3.2.3. Cell and Gene Therapy
14.6.3.2.4. Others
14.6.3.3. India Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization
Size
14.6.3.3.1. Small and Medium Enterprises
14.6.3.3.2. Large Enterprises
14.6.3.4. India Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.3.4.1. Pharmaceutical Companies
14.6.3.4.2. Biotechnology Companies
14.6.3.4.3. Others
14.6.4. New Zealand
14.6.4.1. New Zealand Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Services
14.6.4.1.1. Development Services
14.6.4.1.1.1. Process and Chemical Development
14.6.4.1.1.2. Analytical Development
14.6.4.1.1.3. Formulation Development
14.6.4.1.1.4. Others
14.6.4.1.2. Analytical Research Services
14.6.4.1.3. Clinical and Commercial Manufacturing
14.6.4.1.4. Project Management
14.6.4.1.5. Supply Chain Management and Logistics
Services
14.6.4.1.6. Regulatory Services
14.6.4.1.7. Others
14.6.4.2. New Zealand Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.4.2.1. Drug Substance
14.6.4.2.1.1. Active Pharmaceutical Ingredients (API)
14.6.4.2.1.2. Intermediates
14.6.4.2.1.3. Others
14.6.4.2.2. Drug Products
14.6.4.2.2.1. Oral Solids
14.6.4.2.2.1.1. Tablets
14.6.4.2.2.1.2. Capsules
14.6.4.2.2.1.3. Mini-tablets
14.6.4.2.2.1.4. Powder
14.6.4.2.2.1.5. Others
14.6.4.2.2.2. Semi-solid
14.6.4.2.2.2.1. Creams
14.6.4.2.2.2.2. Ointments
14.6.4.2.2.2.3. Gels
14.6.4.2.2.2.4. Others
14.6.4.2.2.3. Liquid
14.6.4.2.2.4. Inhalation
14.6.4.2.2.5. Sterile
14.6.4.2.2.6. Others
14.6.4.2.3. Cell and Gene Therapy
14.6.4.2.4. Others
14.6.4.3. New Zealand Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Organization Size
14.6.4.3.1. Small and Medium Enterprises
14.6.4.3.2. Large Enterprises
14.6.4.4. New Zealand Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.4.4.1. Pharmaceutical Companies
14.6.4.4.2. Biotechnology Companies
14.6.4.4.3. Others
14.6.5. Australia
14.6.5.1. Australia Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Services
14.6.5.1.1. Development Services
14.6.5.1.1.1. Process and Chemical Development
14.6.5.1.1.2. Analytical Development
14.6.5.1.1.3. Formulation Development
14.6.5.1.1.4. Others
14.6.5.1.2. Analytical Research Services
14.6.5.1.3. Clinical and Commercial Manufacturing
14.6.5.1.4. Project Management
14.6.5.1.5. Supply Chain Management and Logistics Services
14.6.5.1.6. Regulatory Services
14.6.5.1.7. Others
14.6.5.2. Australia Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.5.2.1. Drug Substance
14.6.5.2.1.1. Active Pharmaceutical Ingredients (API)
14.6.5.2.1.2. Intermediates
14.6.5.2.1.3. Others
14.6.5.2.2. Drug Products
14.6.5.2.2.1. Oral Solids
14.6.5.2.2.1.1. Tablets
14.6.5.2.2.1.2. Capsules
14.6.5.2.2.1.3. Mini-tablets
14.6.5.2.2.1.4. Powder
14.6.5.2.2.1.5. Others
14.6.5.2.2.2. Semi-solid
14.6.5.2.2.2.1. Creams
14.6.5.2.2.2.2. Ointments
14.6.5.2.2.2.3. Gels
14.6.5.2.2.2.4. Others
14.6.5.2.2.3. Liquid
14.6.5.2.2.4. Inhalation
14.6.5.2.2.5. Sterile
14.6.5.2.2.6. Others
14.6.5.2.3. Cell and Gene Therapy
14.6.5.2.4. Others
14.6.5.3. Australia Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Organization Size
14.6.5.3.1. Small and Medium Enterprises
14.6.5.3.2. Large Enterprises
14.6.5.4. Australia Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
End Users
14.6.5.4.1. Pharmaceutical Companies
14.6.5.4.2. Biotechnology Companies
14.6.5.4.3. Others
14.6.6. South Korea
14.6.6.1. South Korea Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Services
14.6.6.1.1. Development Services
14.6.6.1.1.1. Process and Chemical Development
14.6.6.1.1.2. Analytical Development
14.6.6.1.1.3. Formulation Development
14.6.6.1.1.4. Others
14.6.6.1.2. Analytical Research Services
14.6.6.1.3. Clinical and Commercial Manufacturing
14.6.6.1.4. Project Management
14.6.6.1.5. Supply Chain Management and Logistics
Services
14.6.6.1.6. Regulatory Services
14.6.6.1.7. Others
14.6.6.2. South Korea Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.6.2.1. Drug Substance
14.6.6.2.1.1. Active Pharmaceutical Ingredients (API)
14.6.6.2.1.2. Intermediates
14.6.6.2.1.3. Others
14.6.6.2.2. Drug Products
14.6.6.2.2.1. Oral Solids
14.6.6.2.2.1.1. Tablets
14.6.6.2.2.1.2. Capsules
14.6.6.2.2.1.3. Mini-tablets
14.6.6.2.2.1.4. Powder
14.6.6.2.2.1.5. Others
14.6.6.2.2.2. Semi-solid
14.6.6.2.2.2.1. Creams
14.6.6.2.2.2.2. Ointments
14.6.6.2.2.2.3. Gels
14.6.6.2.2.2.4. Others
14.6.6.2.2.3. Liquid
14.6.6.2.2.4. Inhalation
14.6.6.2.2.5. Sterile
14.6.6.2.2.6. Others
14.6.6.2.3. Cell and Gene Therapy
14.6.6.2.4. Others
14.6.6.3. South Korea Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Organization Size
14.6.6.3.1. Small and Medium Enterprises
14.6.6.3.2. Large Enterprises
14.6.6.4. South Korea Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
End Users
14.6.6.4.1. Pharmaceutical Companies
14.6.6.4.2. Biotechnology Companies
14.6.6.4.3. Others
14.6.7. Southeast Asia
14.6.7.1. Southeast Asia Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Services
14.6.7.1.1. Development Services
14.6.7.1.1.1. Process and Chemical Development
14.6.7.1.1.2. Analytical Development
14.6.7.1.1.3. Formulation Development
14.6.7.1.1.4. Others
14.6.7.1.2. Analytical Research Services
14.6.7.1.3. Clinical and Commercial Manufacturing
14.6.7.1.4. Project Management
14.6.7.1.5. Supply Chain Management and Logistics
Services
14.6.7.1.6. Regulatory Services
14.6.7.1.7. Others
14.6.7.2. Southeast Asia Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.7.2.1. Drug Substance
14.6.7.2.1.1. Active Pharmaceutical Ingredients (API)
14.6.7.2.1.2. Intermediates
14.6.7.2.1.3. Others
14.6.7.2.2. Drug Products
14.6.7.2.2.1. Oral Solids
14.6.7.2.2.1.1. Tablets
14.6.7.2.2.1.2. Capsules
14.6.7.2.2.1.3. Mini-tablets
14.6.7.2.2.1.4. Powder
14.6.7.2.2.1.5. Others
14.6.7.2.2.2. Semi-solid
14.6.7.2.2.2.1. Creams
14.6.7.2.2.2.2. Ointments
14.6.7.2.2.2.3. Gels
14.6.7.2.2.2.4. Others
14.6.7.2.2.3. Liquid
14.6.7.2.2.4. Inhalation
14.6.7.2.2.5. Sterile
14.6.7.2.2.6. Others
14.6.7.2.3. Cell and Gene Therapy
14.6.7.2.4. Others
14.6.7.3. Southeast Asia Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Organization Size
14.6.7.3.1. Small and Medium Enterprises
14.6.7.3.2. Large Enterprises
14.6.7.4. Southeast Asia Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
End Users
14.6.7.4.1. Pharmaceutical Companies
14.6.7.4.2. Biotechnology Companies
14.6.7.4.3. Others
14.6.7.5. Southeast Asia Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1. Rest of Asia Pacific Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Services
14.6.8.1.1. Development Services
14.6.8.1.1.1. Process and Chemical Development
14.6.8.1.1.2. Analytical Development
14.6.8.1.1.3. Formulation Development
14.6.8.1.1.4. Others
14.6.8.1.2. Analytical Research Services
14.6.8.1.3. Clinical and Commercial Manufacturing
14.6.8.1.4. Project Management
14.6.8.1.5. Supply Chain Management and Logistics
Services
14.6.8.1.6. Regulatory Services
14.6.8.1.7. Others
14.6.8.2. Rest of Asia Pacific Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.8.2.1. Drug Substance
14.6.8.2.1.1. Active Pharmaceutical Ingredients (API)
14.6.8.2.1.2. Intermediates
14.6.8.2.1.3. Others
14.6.8.2.2. Drug Products
14.6.8.2.2.1. Oral Solids
14.6.8.2.2.1.1. Tablets
14.6.8.2.2.1.2. Capsules
14.6.8.2.2.1.3. Mini-tablets
14.6.8.2.2.1.4. Powder
14.6.8.2.2.1.5. Others
14.6.8.2.2.2. Semi-solid
14.6.8.2.2.2.1. Creams
14.6.8.2.2.2.2. Ointments
14.6.8.2.2.2.3. Gels
14.6.8.2.2.2.4. Others
14.6.8.2.2.3. Liquid
14.6.8.2.2.4. Inhalation
14.6.8.2.2.5. Sterile
14.6.8.2.2.6. Others
14.6.8.2.3. Cell and Gene Therapy
14.6.8.2.4. Others
14.6.8.3. Rest of Asia Pacific Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Organization Size
14.6.8.3.1. Small and Medium Enterprises
14.6.8.3.2. Large Enterprises
14.6.8.4. Rest of Asia Pacific Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
End Users
14.6.8.4.1. Pharmaceutical Companies
14.6.8.4.2. Biotechnology Companies
14.6.8.4.3. Others
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Services
14.7.3. By Application
14.7.4. By Organization Size
14.7.5. By End Users
15. Middle East and Africa Contract Development
and Manufacturing Organizations (CDMOs) Market Analysis and Forecasts, 2021 -
2029
15.1. Overview
15.1.1. Middle East and Africa Contract Development
and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn)
15.2. Middle East and Africa Contract Development
and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts,
By Services
15.2.1. Development Services
15.2.1.1. Process and Chemical Development
15.2.1.2. Analytical Development
15.2.1.3. Formulation Development
15.2.1.4. Others
15.2.2. Analytical Research Services
15.2.3. Clinical and Commercial Manufacturing
15.2.4. Project Management
15.2.5. Supply Chain Management and Logistics
Services
15.2.6. Regulatory Services
15.2.7. Others
15.3. Middle East and Africa Contract Development
and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts,
By Application
15.3.1. Drug Substance
15.3.1.1. Active Pharmaceutical Ingredients (API)
15.3.1.2. Intermediates
15.3.1.3. Others
15.3.2. Drug Products
15.3.2.1. Oral Solids
15.3.2.1.1. Tablets
15.3.2.1.2. Capsules
15.3.2.1.3. Mini-tablets
15.3.2.1.4. Powder
15.3.2.1.5. Others
15.3.2.2. Semi-solid
15.3.2.2.1. Creams
15.3.2.2.2. Ointments
15.3.2.2.3. Gels
15.3.2.2.4. Others
15.3.2.3. Liquid
15.3.2.4. Inhalation
15.3.2.5. Sterile
15.3.2.6. Others
15.3.3. Cell and Gene Therapy
15.3.4. Others
15.4. Middle East and Africa Contract Development
and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts,
By Organization Size
15.4.1. Small and Medium Enterprises
15.4.2. Large Enterprises
15.5. Middle East and Africa Contract Development
and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts,
By End Users
15.5.1. Pharmaceutical Companies
15.5.2. Biotechnology Companies
15.5.3. Others
15.6. Middle East and Africa Contract Development
and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts,
By Country
15.6.1. Saudi Arabia
15.6.1.1. Saudi Arabia Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Services
15.6.1.1.1. Development Services
15.6.1.1.1.1. Process and Chemical Development
15.6.1.1.1.2. Analytical Development
15.6.1.1.1.3. Formulation Development
15.6.1.1.1.4. Others
15.6.1.1.2. Analytical Research Services
15.6.1.1.3. Clinical and Commercial Manufacturing
15.6.1.1.4. Project Management
15.6.1.1.5. Supply Chain Management and Logistics
Services
15.6.1.1.6. Regulatory Services
15.6.1.1.7. Others
15.6.1.2. Saudi Arabia Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.1.2.1. Drug Substance
15.6.1.2.1.1. Active Pharmaceutical Ingredients (API)
15.6.1.2.1.2. Intermediates
15.6.1.2.1.3. Others
15.6.1.2.2. Drug Products
15.6.1.2.2.1. Oral Solids
15.6.1.2.2.1.1. Tablets
15.6.1.2.2.1.2. Capsules
15.6.1.2.2.1.3. Mini-tablets
15.6.1.2.2.1.4. Powder
15.6.1.2.2.1.5. Others
15.6.1.2.2.2. Semi-solid
15.6.1.2.2.2.1. Creams
15.6.1.2.2.2.2. Ointments
15.6.1.2.2.2.3. Gels
15.6.1.2.2.2.4. Others
15.6.1.2.2.3. Liquid
15.6.1.2.2.4. Inhalation
15.6.1.2.2.5. Sterile
15.6.1.2.2.6. Others
15.6.1.2.3. Cell and Gene Therapy
15.6.1.2.4. Others
15.6.1.3. Saudi Arabia Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Organization Size
15.6.1.3.1. Small and Medium Enterprises
15.6.1.3.2. Large Enterprises
15.6.1.4. Saudi Arabia Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
End Users
15.6.1.4.1. Pharmaceutical Companies
15.6.1.4.2. Biotechnology Companies
15.6.1.4.3. Others
15.6.2. UAE
15.6.2.1. UAE Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Services
15.6.2.1.1. Development Services
15.6.2.1.1.1. Process and Chemical Development
15.6.2.1.1.2. Analytical Development
15.6.2.1.1.3. Formulation Development
15.6.2.1.1.4. Others
15.6.2.1.2. Analytical Research Services
15.6.2.1.3. Clinical and Commercial Manufacturing
15.6.2.1.4. Project Management
15.6.2.1.5. Supply Chain Management and Logistics
Services
15.6.2.1.6. Regulatory Services
15.6.2.1.7. Others
15.6.2.2. UAE Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Application
15.6.2.2.1. Drug Substance
15.6.2.2.1.1. Active Pharmaceutical Ingredients (API)
15.6.2.2.1.2. Intermediates
15.6.2.2.1.3. Others
15.6.2.2.2. Drug Products
15.6.2.2.2.1. Oral Solids
15.6.2.2.2.1.1. Tablets
15.6.2.2.2.1.2. Capsules
15.6.2.2.2.1.3. Mini-tablets
15.6.2.2.2.1.4. Powder
15.6.2.2.2.1.5. Others
15.6.2.2.2.2. Semi-solid
15.6.2.2.2.2.1. Creams
15.6.2.2.2.2.2. Ointments
15.6.2.2.2.2.3. Gels
15.6.2.2.2.2.4. Others
15.6.2.2.2.3. Liquid
15.6.2.2.2.4. Inhalation
15.6.2.2.2.5. Sterile
15.6.2.2.2.6. Others
15.6.2.2.3. Cell and Gene Therapy
15.6.2.2.4. Others
15.6.2.3. UAE Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization
Size
15.6.2.3.1. Small and Medium Enterprises
15.6.2.3.2. Large Enterprises
15.6.2.4. UAE Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.2.4.1. Pharmaceutical Companies
15.6.2.4.2. Biotechnology Companies
15.6.2.4.3. Others
15.6.3. Egypt
15.6.3.1. Egypt Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Services
15.6.3.1.1. Development Services
15.6.3.1.1.1. Process and Chemical Development
15.6.3.1.1.2. Analytical Development
15.6.3.1.1.3. Formulation Development
15.6.3.1.1.4. Others
15.6.3.1.2. Analytical Research Services
15.6.3.1.3. Clinical and Commercial Manufacturing
15.6.3.1.4. Project Management
15.6.3.1.5. Supply Chain Management and Logistics
Services
15.6.3.1.6. Regulatory Services
15.6.3.1.7. Others
15.6.3.2. Egypt Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Application
15.6.3.2.1. Drug Substance
15.6.3.2.1.1. Active Pharmaceutical Ingredients (API)
15.6.3.2.1.2. Intermediates
15.6.3.2.1.3. Others
15.6.3.2.2. Drug Products
15.6.3.2.2.1. Oral Solids
15.6.3.2.2.1.1. Tablets
15.6.3.2.2.1.2. Capsules
15.6.3.2.2.1.3. Mini-tablets
15.6.3.2.2.1.4. Powder
15.6.3.2.2.1.5. Others
15.6.3.2.2.2. Semi-solid
15.6.3.2.2.2.1. Creams
15.6.3.2.2.2.2. Ointments
15.6.3.2.2.2.3. Gels
15.6.3.2.2.2.4. Others
15.6.3.2.2.3. Liquid
15.6.3.2.2.4. Inhalation
15.6.3.2.2.5. Sterile
15.6.3.2.2.6. Others
15.6.3.2.3. Cell and Gene Therapy
15.6.3.2.4. Others
15.6.3.3. Egypt Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization
Size
15.6.3.3.1. Small and Medium Enterprises
15.6.3.3.2. Large Enterprises
15.6.3.4. Egypt Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.3.4.1. Pharmaceutical Companies
15.6.3.4.2. Biotechnology Companies
15.6.3.4.3. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Services
15.6.4.1.1. Development Services
15.6.4.1.1.1. Process and Chemical Development
15.6.4.1.1.2. Analytical Development
15.6.4.1.1.3. Formulation Development
15.6.4.1.1.4. Others
15.6.4.1.2. Analytical Research Services
15.6.4.1.3. Clinical and Commercial Manufacturing
15.6.4.1.4. Project Management
15.6.4.1.5. Supply Chain Management and Logistics
Services
15.6.4.1.6. Regulatory Services
15.6.4.1.7. Others
15.6.4.2. Kuwait Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Application
15.6.4.2.1. Drug Substance
15.6.4.2.1.1. Active Pharmaceutical Ingredients (API)
15.6.4.2.1.2. Intermediates
15.6.4.2.1.3. Others
15.6.4.2.2. Drug Products
15.6.4.2.2.1. Oral Solids
15.6.4.2.2.1.1. Tablets
15.6.4.2.2.1.2. Capsules
15.6.4.2.2.1.3. Mini-tablets
15.6.4.2.2.1.4. Powder
15.6.4.2.2.1.5. Others
15.6.4.2.2.2. Semi-solid
15.6.4.2.2.2.1. Creams
15.6.4.2.2.2.2. Ointments
15.6.4.2.2.2.3. Gels
15.6.4.2.2.2.4. Others
15.6.4.2.2.3. Liquid
15.6.4.2.2.4. Inhalation
15.6.4.2.2.5. Sterile
15.6.4.2.2.6. Others
15.6.4.2.3. Cell and Gene Therapy
15.6.4.2.4. Others
15.6.4.3. Kuwait Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization
Size
15.6.4.3.1. Small and Medium Enterprises
15.6.4.3.2. Large Enterprises
15.6.4.4. Kuwait Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.4.4.1. Pharmaceutical Companies
15.6.4.4.2. Biotechnology Companies
15.6.4.4.3. Others
15.6.5. South Africa
15.6.5.1. South Africa Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Services
15.6.5.1.1. Development Services
15.6.5.1.1.1. Process and Chemical Development
15.6.5.1.1.2. Analytical Development
15.6.5.1.1.3. Formulation Development
15.6.5.1.1.4. Others
15.6.5.1.2. Analytical Research Services
15.6.5.1.3. Clinical and Commercial Manufacturing
15.6.5.1.4. Project Management
15.6.5.1.5. Supply Chain Management and Logistics
Services
15.6.5.1.6. Regulatory Services
15.6.5.1.7. Others
15.6.5.2. South Africa Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.5.2.1. Drug Substance
15.6.5.2.1.1. Active Pharmaceutical Ingredients (API)
15.6.5.2.1.2. Intermediates
15.6.5.2.1.3. Others
15.6.5.2.2. Drug Products
15.6.5.2.2.1. Oral Solids
15.6.5.2.2.1.1. Tablets
15.6.5.2.2.1.2. Capsules
15.6.5.2.2.1.3. Mini-tablets
15.6.5.2.2.1.4. Powder
15.6.5.2.2.1.5. Others
15.6.5.2.2.2. Semi-solid
15.6.5.2.2.2.1. Creams
15.6.5.2.2.2.2. Ointments
15.6.5.2.2.2.3. Gels
15.6.5.2.2.2.4. Others
15.6.5.2.2.3. Liquid
15.6.5.2.2.4. Inhalation
15.6.5.2.2.5. Sterile
15.6.5.2.2.6. Others
15.6.5.2.3. Cell and Gene Therapy
15.6.5.2.4. Others
15.6.5.3. South Africa Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Organization Size
15.6.5.3.1. Small and Medium Enterprises
15.6.5.3.2. Large Enterprises
15.6.5.4. South Africa Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
End Users
15.6.5.4.1. Pharmaceutical Companies
15.6.5.4.2. Biotechnology Companies
15.6.5.4.3. Others
15.6.6. Rest of Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Contract
Development and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and
Forecasts, By Services
15.6.6.1.1. Development Services
15.6.6.1.1.1. Process and Chemical Development
15.6.6.1.1.2. Analytical Development
15.6.6.1.1.3. Formulation Development
15.6.6.1.1.4. Others
15.6.6.1.2. Analytical Research Services
15.6.6.1.3. Clinical and Commercial Manufacturing
15.6.6.1.4. Project Management
15.6.6.1.5. Supply Chain Management and Logistics
Services
15.6.6.1.6. Regulatory Services
15.6.6.1.7. Others
15.6.6.2. Rest of Middle East & Africa Contract
Development and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.6.2.1. Drug Substance
15.6.6.2.1.1. Active Pharmaceutical Ingredients (API)
15.6.6.2.1.2. Intermediates
15.6.6.2.1.3. Others
15.6.6.2.2. Drug Products
15.6.6.2.2.1. Oral Solids
15.6.6.2.2.1.1. Tablets
15.6.6.2.2.1.2. Capsules
15.6.6.2.2.1.3. Mini-tablets
15.6.6.2.2.1.4. Powder
15.6.6.2.2.1.5. Others
15.6.6.2.2.2. Semi-solid
15.6.6.2.2.2.1. Creams
15.6.6.2.2.2.2. Ointments
15.6.6.2.2.2.3. Gels
15.6.6.2.2.2.4. Others
15.6.6.2.2.3. Liquid
15.6.6.2.2.4. Inhalation
15.6.6.2.2.5. Sterile
15.6.6.2.2.6. Others
15.6.6.2.3. Cell and Gene Therapy
15.6.6.2.4. Others
15.6.6.3. Rest of Middle East & Africa Contract
Development and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and
Forecasts, By Organization Size
15.6.6.3.1. Small and Medium Enterprises
15.6.6.3.2. Large Enterprises
15.6.6.4. Rest of Middle East & Africa Contract
Development and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and
Forecasts, By End Users
15.6.6.4.1. Pharmaceutical Companies
15.6.6.4.2. Biotechnology Companies
15.6.6.4.3. Others
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Services
15.7.3. By Application
15.7.4. By Organization Size
15.7.5. By End Users
16. Latin America Contract Development and
Manufacturing Organizations (CDMOs) Market Analysis and Forecasts, 2021 - 2029
16.1. Overview
16.1.1. Latin America Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn)
16.2. Latin America Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Services
16.2.1. Development Services
16.2.1.1. Process and Chemical Development
16.2.1.2. Analytical Development
16.2.1.3. Formulation Development
16.2.1.4. Others
16.2.2. Analytical Research Services
16.2.3. Clinical and Commercial Manufacturing
16.2.4. Project Management
16.2.5. Supply Chain Management and Logistics
Services
16.2.6. Regulatory Services
16.2.7. Others
16.3. Latin America Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Application
16.3.1. Drug Substance
16.3.1.1. Active Pharmaceutical Ingredients (API)
16.3.1.2. Intermediates
16.3.1.3. Others
16.3.2. Drug Products
16.3.2.1. Oral Solids
16.3.2.1.1. Tablets
16.3.2.1.2. Capsules
16.3.2.1.3. Mini-tablets
16.3.2.1.4. Powder
16.3.2.1.5. Others
16.3.2.2. Semi-solid
16.3.2.2.1. Creams
16.3.2.2.2. Ointments
16.3.2.2.3. Gels
16.3.2.2.4. Others
16.3.2.3. Liquid
16.3.2.4. Inhalation
16.3.2.5. Sterile
16.3.2.6. Others
16.3.3. Cell and Gene Therapy
16.3.4. Others
16.4. Latin America Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Organization Size
16.4.1. Small and Medium Enterprises
16.4.2. Large Enterprises
16.5. Latin America Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
End Users
16.5.1. Pharmaceutical Companies
16.5.2. Biotechnology Companies
16.5.3. Others
16.6. Latin America Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Country
16.6.1. Brazil
16.6.1.1. Brazil Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Services
16.6.1.1.1. Development Services
16.6.1.1.1.1. Process and Chemical Development
16.6.1.1.1.2. Analytical Development
16.6.1.1.1.3. Formulation Development
16.6.1.1.1.4. Others
16.6.1.1.2. Analytical Research Services
16.6.1.1.3. Clinical and Commercial Manufacturing
16.6.1.1.4. Project Management
16.6.1.1.5. Supply Chain Management and Logistics
Services
16.6.1.1.6. Regulatory Services
16.6.1.1.7. Others
16.6.1.2. Brazil Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Application
16.6.1.2.1. Drug Substance
16.6.1.2.1.1. Active Pharmaceutical Ingredients (API)
16.6.1.2.1.2. Intermediates
16.6.1.2.1.3. Others
16.6.1.2.2. Drug Products
16.6.1.2.2.1. Oral Solids
16.6.1.2.2.1.1. Tablets
16.6.1.2.2.1.2. Capsules
16.6.1.2.2.1.3. Mini-tablets
16.6.1.2.2.1.4. Powder
16.6.1.2.2.1.5. Others
16.6.1.2.2.2. Semi-solid
16.6.1.2.2.2.1. Creams
16.6.1.2.2.2.2. Ointments
16.6.1.2.2.2.3. Gels
16.6.1.2.2.2.4. Others
16.6.1.2.2.3. Liquid
16.6.1.2.2.4. Inhalation
16.6.1.2.2.5. Sterile
16.6.1.2.2.6. Others
16.6.1.2.3. Cell and Gene Therapy
16.6.1.2.4. Others
16.6.1.3. Brazil Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By Organization
Size
16.6.1.3.1. Small and Medium Enterprises
16.6.1.3.2. Large Enterprises
16.6.1.4. Brazil Contract Development and Manufacturing
Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.1.4.1. Pharmaceutical Companies
16.6.1.4.2. Biotechnology Companies
16.6.1.4.3. Others
16.6.2. Argentina
16.6.2.1. Argentina Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Services
16.6.2.1.1. Development Services
16.6.2.1.1.1. Process and Chemical Development
16.6.2.1.1.2. Analytical Development
16.6.2.1.1.3. Formulation Development
16.6.2.1.1.4. Others
16.6.2.1.2. Analytical Research Services
16.6.2.1.3. Clinical and Commercial Manufacturing
16.6.2.1.4. Project Management
16.6.2.1.5. Supply Chain Management and Logistics
Services
16.6.2.1.6. Regulatory Services
16.6.2.1.7. Others
16.6.2.2. Argentina Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Application
16.6.2.2.1. Drug Substance
16.6.2.2.1.1. Active Pharmaceutical Ingredients (API)
16.6.2.2.1.2. Intermediates
16.6.2.2.1.3. Others
16.6.2.2.2. Drug Products
16.6.2.2.2.1. Oral Solids
16.6.2.2.2.1.1. Tablets
16.6.2.2.2.1.2. Capsules
16.6.2.2.2.1.3. Mini-tablets
16.6.2.2.2.1.4. Powder
16.6.2.2.2.1.5. Others
16.6.2.2.2.2. Semi-solid
16.6.2.2.2.2.1. Creams
16.6.2.2.2.2.2. Ointments
16.6.2.2.2.2.3. Gels
16.6.2.2.2.2.4. Others
16.6.2.2.2.3. Liquid
16.6.2.2.2.4. Inhalation
16.6.2.2.2.5. Sterile
16.6.2.2.2.6. Others
16.6.2.2.3. Cell and Gene Therapy
16.6.2.2.4. Others
16.6.2.3. Argentina Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
Organization Size
16.6.2.3.1. Small and Medium Enterprises
16.6.2.3.2. Large Enterprises
16.6.2.4. Argentina Contract Development and
Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts, By
End Users
16.6.2.4.1. Pharmaceutical Companies
16.6.2.4.2. Biotechnology Companies
16.6.2.4.3. Others
16.6.3. Rest of Latin America
16.6.3.1. Rest of Latin America Contract Development
and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts,
By Services
16.6.3.1.1. Development Services
16.6.3.1.1.1. Process and Chemical Development
16.6.3.1.1.2. Analytical Development
16.6.3.1.1.3. Formulation Development
16.6.3.1.1.4. Others
16.6.3.1.2. Analytical Research Services
16.6.3.1.3. Clinical and Commercial Manufacturing
16.6.3.1.4. Project Management
16.6.3.1.5. Supply Chain Management and Logistics
Services
16.6.3.1.6. Regulatory Services
16.6.3.1.7. Others
16.6.3.2. Rest of Latin America Contract Development
and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts,
By Application
16.6.3.2.1. Drug Substance
16.6.3.2.1.1. Active Pharmaceutical Ingredients (API)
16.6.3.2.1.2. Intermediates
16.6.3.2.1.3. Others
16.6.3.2.2. Drug Products
16.6.3.2.2.1. Oral Solids
16.6.3.2.2.1.1. Tablets
16.6.3.2.2.1.2. Capsules
16.6.3.2.2.1.3. Mini-tablets
16.6.3.2.2.1.4. Powder
16.6.3.2.2.1.5. Others
16.6.3.2.2.2. Semi-solid
16.6.3.2.2.2.1. Creams
16.6.3.2.2.2.2. Ointments
16.6.3.2.2.2.3. Gels
16.6.3.2.2.2.4. Others
16.6.3.2.2.3. Liquid
16.6.3.2.2.4. Inhalation
16.6.3.2.2.5. Sterile
16.6.3.2.2.6. Others
16.6.3.2.3. Cell and Gene Therapy
16.6.3.2.4. Others
16.6.3.3. Rest of Latin America Contract Development
and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts,
By Organization Size
16.6.3.3.1. Small and Medium Enterprises
16.6.3.3.2. Large Enterprises
16.6.3.4. Rest of Latin America Contract Development
and Manufacturing Organizations (CDMOs) Market Revenue (US$ Mn) and Forecasts,
By End Users
16.6.3.4.1. Pharmaceutical Companies
16.6.3.4.2. Biotechnology Companies
16.6.3.4.3. Others
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Services
16.7.3. By Application
16.7.4. By Organization Size
16.7.5. By End Users
17. Competitive Benchmarking
17.1. Market Share Analysis, 2020
17.2. Global Presence and Growth Strategies
17.2.1. Mergers and Acquisitions
17.2.2. Product Launches
17.2.3. Investments Trends
17.2.4. R&D Initiatives
18. Player Profiles
18.1. Adaptalogix
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. AGC Biologics
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Ardena Holding NV
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. Catalent, Inc
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. CordenPharma
International
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. Eurofins Scientific
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. FAMAR Health Care Services
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. Fujifilm Diosynth Biotechnologies
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. KBI Biopharma
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. Lonza
18.10.1. Company Details
18.10.2. Company Overview
18.10.3. Product Offerings
18.10.4. Key Developments
18.10.5. Financial Analysis
18.10.6. SWOT Analysis
18.10.7. Business Strategies
18.11. mAbxience
18.11.1. Company Details
18.11.2. Company Overview
18.11.3. Product Offerings
18.11.4. Key Developments
18.11.5. Financial Analysis
18.11.6. SWOT Analysis
18.11.7. Business Strategies
18.12. Merck KGaA
18.12.1. Company Details
18.12.2. Company Overview
18.12.3. Product Offerings
18.12.4. Key Developments
18.12.5. Financial Analysis
18.12.6. SWOT Analysis
18.12.7. Business Strategies
18.13. Pfizer Inc.
18.13.1. Company Details
18.13.2. Company Overview
18.13.3. Product Offerings
18.13.4. Key Developments
18.13.5. Financial Analysis
18.13.6. SWOT Analysis
18.13.7. Business Strategies
18.14. Recipharm AB
18.14.1. Company Details
18.14.2. Company Overview
18.14.3. Product Offerings
18.14.4. Key Developments
18.14.5. Financial Analysis
18.14.6. SWOT Analysis
18.14.7. Business Strategies
18.15. Shanghai ChemPartner
18.15.1. Company Details
18.15.2. Company Overview
18.15.3. Product Offerings
18.15.4. Key Developments
18.15.5. Financial Analysis
18.15.6. SWOT Analysis
18.15.7. Business Strategies
18.16. Siegfried Holding AG
18.16.1. Company Details
18.16.2. Company Overview
18.16.3. Product Offerings
18.16.4. Key Developments
18.16.5. Financial Analysis
18.16.6. SWOT Analysis
18.16.7. Business Strategies
18.17. SK biotek
18.17.1. Company Details
18.17.2. Company Overview
18.17.3. Product Offerings
18.17.4. Key Developments
18.17.5. Financial Analysis
18.17.6. SWOT Analysis
18.17.7. Business Strategies
18.18. Thermo Fisher Scientific Inc.
18.18.1. Company Details
18.18.2. Company Overview
18.18.3. Product Offerings
18.18.4. Key Developments
18.18.5. Financial Analysis
18.18.6. SWOT Analysis
18.18.7. Business Strategies
18.19. Other Market Participants
19. Key Findings
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.